Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19

Transfus Apher Sci. 2020 Aug;59(4):102817. doi: 10.1016/j.transci.2020.102817. Epub 2020 May 21.

Abstract

Passive immunotherapy with plasma derived from patients convalescent from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that Blood Establishments are prepared to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution and control of use of the product. This position paper is aimed to give recommendations on biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.

Keywords: COVID-19; Immune plasma.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antibodies, Viral / blood
  • Betacoronavirus / immunology*
  • Blood Component Removal / methods
  • Blood Donors
  • COVID-19
  • COVID-19 Serotherapy
  • Coronavirus Infections / blood
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy*
  • Donor Selection / standards
  • Humans
  • Immune Sera / adverse effects
  • Immune Sera / isolation & purification
  • Immunization, Passive* / adverse effects
  • Immunization, Passive* / methods
  • Pandemics
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy*
  • Product Labeling
  • Risk
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Immune Sera